Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On December 10, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) entered into separate, privately negotiated repurchase agreements with certain
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document Description 99.1 Press release announcing the partial notes repurchase, dated December 11,